BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer..

波士顿，2024年5月30日（环球通讯社）--Monte Rosa Therapeutics，Inc.（纳斯达克：GLUE），一家开发新型分子胶降解剂（MGD）药物的临床阶段生物技术公司，今天宣布三项领导团队晋升立即生效：Sharon Townson博士，首席科学官；Phil Nickson博士，J.D.，首席商务和法律官；首席运营官Jennifer Champoux。。

“I am very pleased to announce the well-deserved promotions of Sharon, Phil and Jennifer to expanded roles on our leadership team,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “Each has played a critical role in advancing our pipeline programs, enhancing our QuEEN™ drug discovery engine, developing relationships with premier biopharma companies, and building an outstanding organization.

Monte Rosa Therapeutics首席执行官Markus Warmuth医学博士表示：“我非常高兴地宣布，Sharon、Phil和Jennifer当之无愧地被提升为我们领导团队的扩大角色。”。“每个人都在推进我们的管道计划，增强我们的QuEEN™药物发现引擎，发展与一流生物制药公司的关系以及建立一个杰出的组织方面发挥了关键作用。

I look forward to continued work and collaboration with this talented group as we advance our pipeline programs targeting cancers and immune-related diseases and further leverage the potential of our AI/ML-driven discovery engine.”.

随着我们推进针对癌症和免疫相关疾病的管道计划，并进一步利用我们的AI/ML驱动的发现引擎的潜力，我期待着与这一才华横溢的团队继续合作。”。

Sharon Townson, Ph.D., promoted to Chief Scientific Officer, joined Monte Rosa as Chief Technology Officer and brings expertise in molecular glues and targeted protein degradation technology platforms. She joined the Company from Kymera Therapeutics, where she served as Executive Director of Platform Biology.

SharonTownson博士晋升为首席科学官，加入Monte Rosa担任首席技术官，并在分子胶和靶向蛋白质降解技术平台方面拥有专业知识。她从Kymera Therapeutics加入该公司，担任平台生物学的执行董事。

Previously, she was on the leadership team of Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Sharon began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology..

此前，她是Warp Drive Bio的领导团队成员，负责开发针对KRAS的新型分子胶方法。莎伦以结构生物学家的身份在辉瑞开始了她的职业生涯，并拥有曼彻斯特大学理工学院的结构生物学和生物化学博士学位。。

Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer, joined the Company as General Counsel and has provided general legal support, including work on intellectual property matters and external business transactions. Phil joined Monte Rosa with over 15 years of life sciences legal experience.

Phil Nickson博士（J.D.）晋升为首席商务官和法律官，加入公司担任总法律顾问，并提供一般法律支持，包括知识产权事务和外部商业交易方面的工作。Phil加入Monte Rosa拥有超过15年的生命科学法律经验。

Previously, he was with Momenta Pharmaceuticals for over 10 years, through the company’s acquisition by Johnson and Johnson. Phil began his legal career with Fish and Richardson in Boston. He holds a J.D. from Suffolk University and a Ph.D. from the University of Manchester..

此前，通过强生公司收购Momenta制药，他在该公司工作了10多年。菲尔在波士顿的费什和理查森开始了他的律师生涯。他拥有萨福克大学的J.D.和曼彻斯特大学的博士学位。。

Jennifer Champoux, promoted to Chief Operating Officer, joined Monte Rosa as Vice President of Operations, leading overall corporate operations and Human Resources. Jen brings over 15 years of diverse operations experience, including site operations, strategic planning, finance, communications, and culture and employee engagement.

Jennifer Champoux晋升为首席运营官，加入Monte Rosa担任运营副总裁，领导公司整体运营和人力资源。Jen拥有超过15年的多元化运营经验，包括现场运营、战略规划、财务、沟通、文化和员工敬业度。

Previously, she was with H3 Biomedicine, leading operations, communications, and finance operations teams. Earlier, Jen was with Novartis Institutes for Biomedical Research, leading operations for the Discovery Chemistry group in Cambridge. She previously worked in various roles at Merck and Array BioPharma.

此前，她曾在H3生物医学公司工作，领导运营、通信和财务运营团队。早些时候，Jen在诺华生物医学研究所工作，负责剑桥发现化学小组的运营。她之前曾在默克和Array BioPharma担任过各种角色。

Jen holds an M.S. in chemistry from Indiana University..

Jen拥有印第安纳大学化学硕士学位。。

About Monte Rosa

关于Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot.

Monte Rosa Therapeutics是一家临床阶段的生物技术公司，为肿瘤学，自身免疫性和炎症性疾病等领域的严重疾病患者开发高选择性分子胶降解剂（MGD）药物。MGD是小分子蛋白质降解剂，有可能治疗许多其他方式（包括其他降解剂）无法治疗的疾病。

Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas.

Monte Rosa的QuEEN™（新底物的定量和工程消除）发现引擎结合了AI指导的化学，多种化学文库，结构生物学和蛋白质组学，以鉴定可降解的蛋白质靶标，并以前所未有的选择性合理设计MGD。QuEEN discovery引擎可以在多个治疗领域访问经过充分验证的生物学的广泛且差异化的目标空间。

Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.

Monte Rosa开发了业界领先的MGD管道，涵盖肿瘤学，自身免疫性和炎症性疾病等领域，并与罗氏公司进行了战略合作，以发现和开发针对癌症和神经系统疾病的MGD，这些疾病以前被认为是不可能药物治疗的。

For more information, visit www.monterosatx.com..

有关更多信息，请访问www.monterosatx.com。。

Investors

投资者

Andrew Funderburk

安德鲁·芬德布鲁克

ir@monterosatx.com

ir@monterosatx.com

Media

媒体

Cory Tromblee, Scient PR

Cory Tromblee，科学公关

media@monterosatx.com

media@monterosatx.com